Prevalence of Heparin induced thrombocytopenia among Indian patients who underwent Heparin therapy in five cities of India: A cross sectional descriptive study

Background: Thrombocytopenia is the platelet disorder in which the thrombocytes count reduces less than 1.5 lakhs. Medication is the prime management of any treatment, the medicines advised to patients help in curing the disease, however these medications have adverse effects too, these adverse reactions are local and systemic, one such drug used in clotting disorder develops thrombocytopenia and the condition is called Heparin induced thrombocytopenia. The present study aims to study the prevalence of heparin induced thrombocytopenia in multiple cities in India.Materials and Methods: A cross sectional study designed to assess the prevalence of heparin induced thrombocytopenia in India for a period of 11 months from Janaury 2022 to November 2022.A total of 2860 samples were selected from different diagnostic centers at Lucknow, Panipat, Sonipat, Gohana, Delhi all heparin administrated patients samples were collected in the clinical area and who were at risk of developing decreased platelets counts or any skin related symptoms like rashes, petechiae ,redness, red spots were identified.Result: The study was conducted for 2860 samples of which 109 found have heparin induced thrombocytopenia, the prevalence of heparin-induced thrombocytopenia was 3.8.Conclusion: Heparin is used in clotting disorder; the adverse effect of heparin usage can lead to heparin-induced thrombocytopenia. The present study identified the prevalence rate of heparin-induced thrombocytopenia, which help in identifying the complication associated with the heparin therapy and its induced thrombocytopenia.